Fibulin-3 as a diagnostic biomarker in patients with malignant mesothelioma

Basit Öğe Kaydı
dc.contributor.authorKaya H.
dc.contributor.authorDemir M.
dc.contributor.authorTaylan M.
dc.contributor.authorSezgi C.
dc.contributor.authorTanrikulu A.C.
dc.contributor.authorYilmaz S.
dc.contributor.authorBayram M.
dc.date.accessioned2024-04-24T17:58:31Z
dc.date.available2024-04-24T17:58:31Z
dc.date.issued2015
dc.departmentDicle Üniversitesien_US
dc.description.abstractBackground: New tumour biomarkers are being intensely investigated for malignant mesothelioma (MM). Fibulin-3 is produced in MM but its role remains uncertain. The aim of this study was to evaluate the validity of measuring serum fibulin-3 in the diagnosis and prognosis of MM. Materials and Methods: This prospective study was performed on 43 patients and 40 healthy controls who were admitted to our hospital between January 2012 and January 2014. Data from MM patients, including demographic and clinical features, routine laboratory data, levels of serum fibulin-3, and treatment outcomes were defined as potential prognostic factors. The receiver operating characteristic (ROC) curve for fibulin-3 was used to detect the cut-off value with highest sensitivity and specificity. Univariate survival analysis was performed using the Kaplan-Meier method in patients with MM. Afterwards, the possible factors identified with univariate analyses were entered into the cox regression analysis. Results: Our results revealed that patients with MM had significantly higher serum levels of fibulin-3 than controls. The results showed that the best cut-off point was 36.6 ng/ml with an AUC (area under the curve)=0.976, sensitivity=93.0% and specificity=90.0. In our study, the initial significant poor prognostic factors were advanced stage, high white blood cell count, high platelet count, high C-reactive protein (p<0.05 for each variable). Later, according to multivariate analysis the results showed only advanced stage as significant parameter (p=0.040). Conclusions: We determined that real use for serum fibulin-3 was not for prognosis but for diagnosis in MM. Also advanced stage was associated with poor MM prognosis.en_US
dc.identifier.doi10.7314/APJCP.2015.16.4.1403
dc.identifier.endpage1407en_US
dc.identifier.issn1513-7368
dc.identifier.issue4en_US
dc.identifier.pmid25743806
dc.identifier.scopus2-s2.0-84926135762
dc.identifier.scopusqualityQ3
dc.identifier.startpage1403en_US
dc.identifier.urihttps://doi.org/10.7314/APJCP.2015.16.4.1403
dc.identifier.urihttps://hdl.handle.net/11468/23967
dc.identifier.volume16en_US
dc.indekslendigikaynakScopus
dc.indekslendigikaynakPubMed
dc.language.isoenen_US
dc.publisherAsian Pacific Organization for Cancer Preventionen_US
dc.relation.ispartofAsian Pacific Journal of Cancer Prevention
dc.relation.publicationcategoryMakale - Uluslararası Hakemli Dergi - Kurum Öğretim Elemanıen_US
dc.rightsinfo:eu-repo/semantics/openAccessen_US
dc.subjectDiagnosisen_US
dc.subjectMalignant Mesotheliomaen_US
dc.subjectPrognosisen_US
dc.subjectSerum Fibulin-3en_US
dc.titleFibulin-3 as a diagnostic biomarker in patients with malignant mesotheliomaen_US
dc.titleFibulin-3 as a diagnostic biomarker in patients with malignant mesothelioma
dc.typeArticleen_US

Dosyalar

Koleksiyon

Scopus İndeksli Yayınlar Koleksiyonu
PubMed İndeksli Yayın Koleksiyonu